

# LIAISON NES<sup>®</sup>

A molecular diagnostic device purpose-built for point-of-care users.

## Fast, reliable answers in ~15 minutes

Accurate, same-visit results for respiratory infections that enable confident patient care decisions.



Diasorin

# Simplify respiratory infection testing with the LIAISON NES®

LIAISON NES® enables non-laboratory staff to consistently get accurate results for respiratory illnesses in ~15 minutes. It's a simple device that's easy-to-learn, easy-to-use, and easy-to-maintain.



## Point-of-care respiratory testing is associated with:

↓ **25%**

drop in ED length of stay<sup>1</sup>

↓ **70%**

avoided unneeded antibiotics after RSV-positive test<sup>2</sup>

↓ **15%**

reduction of over- and undertreatment for flu A and B<sup>3</sup>

↓ **16%**

decrease in undertreatment of COVID-19<sup>4</sup>

**93% patients believe that point-of-care testing can improve their treatment.<sup>5</sup>**

## 1 sample. 1 test. 4 targets detected.

A single multiplex molecular respiratory assay that delivers rapid differential diagnoses.

Target	PPA <sup>6</sup>	NPA <sup>6</sup>
Influenza A	96.5%	97.2%
Influenza B	97.1%	99.7%
RSV	90.3%	99.8%
COVID-19	98.4%	99.4%

PPA: positive percent agreement; NPA: negative percent agreement

# Make confident, same-visit clinical decisions

<1

minute  
hands-on time

3

steps to  
run testing

~15

minutes  
turnaround time

LIS/EMR\* integration  
with seamless  
connectivity

Improve patient satisfaction, reduce infection spread, and promote antibiotic stewardship by enabling immediate test-and-treat care.

## Simplify at every step



### Effortless implementation

- Requires minimal training
- All-inclusive training kit included



### Streamlined operation

- Remote visibility of operational and results data
- Results integrated into your LIS/EMR\* and Diasorin Cloud



### Hands-off maintenance

- Remote and accelerated troubleshooting
- Firmware updates deployed remotely

## Reduce the need for follow-up testing by 38%<sup>7</sup>



### Improve care without burdening staff

with easy, reliable molecular testing that minimizes operator time, risk of errors, and manual steps.




### Promote financial sustainability

with a molecular point-of-care solution that keeps testing in-house and aligns with dynamic coverage policies.



\*LIS: laboratory information system; EMR: electronic medical record

# Find out how the LIAISON NES<sup>®</sup> can fit into your workflow



## Ordering Information

Product Name	Kit Size	Part Number
LIAISON NES <sup>®</sup> FLU A/B, RSV & COVID-19 Assay	10	NES4450
LIAISON NES <sup>®</sup> FLU A/B, RSV & COVID-19 Control Kit	20 (10 positive, 10 negative)	NES4460

Get started at  
[diasorin.com/liaison-nes](https://diasorin.com/liaison-nes)



### References:

1. Baron A, Peyrony O, Salmons M, et al. Impact of Fast SARS-CoV-2 Molecular Point-Of-Care Testing on Patients' Length of Stay in an Emergency Department. *Microbiol Spectr*. 2022 Aug 31;10(4):e0063622.
2. Ferruggia K. How Rapid RSV Testing Shapes Clinical Decisions and Patient Outcomes. *Pharmacy Times*. Nov 4, 2025. Accessed Feb 2026.
3. Hernandez DR, Pellitteri GP, Kimmich DJ, Heiter BJ, Smeal K, Wolk DM. Near point-of-care adoption of Cepheid Xpert<sup>®</sup> Flu/RSV XC testing within an integrated healthcare delivery network. *Diagn Microbiol Infect Dis*. 2019;94(1):28-29. doi:10.1016/j.diagmicrobio.2018.11.013
4. May L, Robbins EM, Canchola JA, Chugh K, Tran NK. A study to assess the impact of the cobas point-of-care RT-PCR assay (SARS-CoV-2 and Influenza A/B) on patient clinical management in the emergency department of the University of California at Davis Medical Center. *J Clin Virol*. 2023;168:105597. doi:10.1016/j.jcv.2023.105597
5. Lilly CM, Ensom E, Teebagy S, DiMezza D, Dunlap D, Hafer N, Buchholz B, McManus D. Patient Preferences for Point-of-Care Testing: Survey Validation and Results. *Point Care*. 2020 Dec;19(4):112-115. doi:10.1097/poc.0000000000000214.
6. LIAISON NES<sup>®</sup> Flu A/B, RSV & COVID-19 Instructions for Use. DiaSorin; 2026. IFUK.US.NES4450, Rev 1
7. Stockl KM, Tucker J, Beaubrun A, Certa JM, Becker L, Chase JG. Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample. *PLoS One*. 2024;19(11):e0313660. Published 2024 Nov 11. doi:10.1371/journal.pone.0313660doi:10.1016/j.jcv.2023.105597

# Diasorin

Austin, TX

p: +1 (512) 381 4397

w: diasorin.com

## CLIA COMPLEXITY: WAIVED

Refer to the LIAISON NES<sup>®</sup> FLU A/B, RSV & COVID-19 Instructions for Use for complete instructions.

**For In Vitro Diagnostic Use.** Products are region specific and may not be approved in some countries/regions.

©2026 DiaSorin Molecular LLC. All rights reserved. LIAISON is a trademark of DiaSorin Molecular LLC and/or its affiliates, registered in the US and other countries.

BR1129102.US.0226